Novo Nordisk’s weight-loss medication Wegovy (semaglutide) was approved in Japan in March. While it skipped the May round of reimbursement listing, physicians eagerly await the arrival of what would be the first new obesity drug in three decades. Other companies…
HOME > BUSINESS
BUSINESS
- Axcelead to Expand Overseas Biz, Shoots for 130 Billion Yen Sales and 5,000-Plus Researchers
April 13, 2023
- PET Imaging Agent Vizamyl Filed for Additional Use for AD Modifying Drug
April 13, 2023
- Alexion Japan Recalling Ultomiris IV 300 mg/3 mL
April 13, 2023
- Japan Lacks Talent, Ecosystem to Incubate Drug Seeds: Chugai Chair
April 13, 2023
- Astellas, Kyoto University’s CiRA Extend iPS Cell Pact
April 13, 2023
- Astellas Incurs 58 Billion Yen Impairment Loss on Sluggish Evrenzo, Other Factors
April 12, 2023
- Sumitomo’s SaMD for Depression Gets Priority Review; Clinical Trial Launch Eyed within 3 Years
April 12, 2023
- BA.4/5-Based Jab Filed for 6 Months to 4 Years in Japan: Pfizer/BioNTech
April 12, 2023
- Meiji/CSL Seqirus Tie Up for Sales of COVID-19 mRNA Vaccine in Japan
April 12, 2023
- Shionogi Seeks EUA for Xocova in Taiwan
April 12, 2023
- Novo Japan Sales Renew Record in 2022 as Ozempic, Rybelsus Blossom
April 12, 2023
- Wakamoto to Halt Shipments of MaQaid on Quality Issues
April 11, 2023
- Shionogi Begins Global PIIb Stroke Study for Regeneration-Inducing Medicine
April 11, 2023
- MSD Rolls Out 15-Valent Pneumococcal Vaccine Vaxneuvance in Japan
April 11, 2023
- Amgen Eyes Simultaneous Filing in Japan, US, EU for 3 Key Drivers, including Next-Gen BiTE Drug: R&D Chief
April 11, 2023
- Ono/BMS Settles PD-1/PD-L1 Patent Row with Dana-Farber
April 10, 2023
- Generic Shipment Price Rate Likely Rose 1.5% for FY2023 Revision, Weighing on Wholesalers
April 10, 2023
- Sanofi Discontinues Sales of Allegra Dry Syrup in Japan
April 10, 2023
- Insud’s Oral Contraceptive Filed in South Korea: ASKA
April 10, 2023
- Japan Ethical Drug Sales Up 0.6% in February: Crecon
April 10, 2023
ページ
President Joe Biden enacted the Inflation Reduction Act (IRA) on August 16, 2022, significantly affecting Medicare prescription drug coverage and introducing targeted changes to Medicaid, the Children’s Health Insurance Program, and private health insurance. In January 2023, the Centers for…
Japan’s health ministry on April 27 presented an outline of a report to be compiled next month by its key…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…